Cirius Therapeutics has updated it filing for a planned $86 million IPO. The date of the IPO still hasn't been set.

Cirius' lead candidate, MSDC-0602K, is a once daily, oral treatment for NASH. The novel approach targets NASH at the mitochondria level. It is designed to modulate the entry of pyruvate into the mitochondria. Interim Ph IIb results were promising. They included: In the two highest dose groups, at least 50% of patients with high baseline ALT or AST improved to normal range at six months.

In April of 2017, the company completed $40 million series A round. The proceeds were raised to finance the Ph II trials of MSDC-0602K.